RVPHライブシグナル | Getagraph.comで利益を最大化

買う 109399 min ago

@ $4.65

発行日: 14 2月 2024 @ 02:23

リターン: -34.62%

前回のシグナル: 2月 13 - 23:32

前回のシグナル: 売る

リターン: 4.26 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:30):

Stats
本日の出来高	49 613.00
平均出来高	294 580
時価総額	84.87M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.280 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.840
ATR14	$0.0190 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Saxena Parag	Buy	585 366	Pre-Funded Warrant
2023-11-20	Saxena Parag	Buy	585 366	Common Stock Warrant (right to buy)
2023-11-13	Funtleyder Leslie D.	Buy	8 200	Stock Option (right to buy)
2023-11-13	Patel Purav	Buy	8 200	Stock Option (right to buy)
2023-11-13	Saxena Parag	Buy	8 200	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 9 383 157 \| Sell: 2 515 186

ボリューム相関

長: 0.00 (neutral)

短: 0.05 (neutral)

Signal:(56.286) Neutral

Reviva Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関
ISNS	-0.839
APOP	-0.832

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Reviva Pharmaceuticals 相関 - 通貨/商品

0.42
( neutral )

0.47
( neutral )

0.00
( neutral )

0.45
( neutral )

-0.08
( neutral )

-0.42
( neutral )

Reviva Pharmaceuticals 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.250

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.250

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.662

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.